S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

$137.32
-1.36 (-0.98%)
(As of 03/28/2024 ET)
Today's Range
$136.29
$140.07
50-Day Range
$127.73
$147.20
52-Week Range
$89.00
$233.42
Volume
916,873 shs
Average Volume
1.79 million shs
Market Capitalization
$21.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$166.95

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.32 Rating Score
Upside/​Downside
21.6% Upside
$166.95 Price Target
Short Interest
Healthy
3.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.67mentions of Illumina in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$991,676 Bought Last Quarter
Proj. Earnings Growth
162.64%
From $0.91 to $2.39 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.66 out of 5 stars

Medical Sector

70th out of 938 stocks

Analytical Instruments Industry

1st out of 26 stocks

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Illumina (NASDAQ:ILMN) Given Mixed Rating at OTR Global
ILMN May 2024 120.000 put
ILMN Mar 2024 124.000 put
ILMN Mar 2024 155.000 call
ILMN Mar 2024 131.000 put
ILMN Mar 2024 115.000 put
ILMN Mar 2024 127.000 call
Carl Icahn Drops Plans for New Proxy Fight at Illumina
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/28/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,300
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$166.95
High Stock Price Target
$258.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+21.6%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
19 Analysts

Profitability

Net Income
$-1,161,000,000.00
Pretax Margin
-24.80%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$3.68 per share
Book Value
$36.18 per share

Miscellaneous

Free Float
158,693,000
Market Cap
$21.82 billion
Optionable
Optionable
Beta
1.19

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., CFO, Chief Strategy & Corporate Development Officer
    Comp: $787.3k
  • Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
  • Stephanie Campos
    President
  • Mr. Kevin Carl Pegels (Age 57)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 52)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 53)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.06M
  • Ms. Kathryne Gambrell Reeves (Age 55)
    Chief Marketing Officer

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina offers sequencing and array-based solutions for genetic and genomic analysis, catering to a wide range of customers including research centers, academic institutions, and commercial laboratories.
  • The company is developing innovative solutions to accelerate cancer diagnoses, detect minimal residual disease, and enhance post-diagnostic applications, showing a commitment to advancing healthcare.
  • Illumina's multi-cancer early detection test, Galleri, provides a promising avenue for early cancer detection, potentially revolutionizing cancer screening methods.
  • The company's focus on genomics and genetic analysis places it at the forefront of cutting-edge technology in the life sciences industry, offering investors exposure to a rapidly evolving sector.
  • Recent positive market ratings and institutional investor holdings indicate confidence in Illumina's growth potential, which can be appealing to investors seeking long-term opportunities.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Market volatility and fluctuations in the life sciences industry can impact Illumina's stock price, potentially leading to short-term uncertainties for investors.
  • Regulatory challenges and changes in healthcare policies may affect the demand for Illumina's products and services, introducing risks related to evolving industry regulations.
  • Competition from other companies in the genomics and genetic analysis space could pressure Illumina's market share and margins, posing challenges to sustained growth and profitability.
  • Investing in analytical instrument companies like Illumina requires understanding complex technologies and industry-specific terms, which may pose a learning curve for some investors unfamiliar with the sector.
  • Fluctuations in research funding, particularly in government institutions and academic centers, can impact Illumina's revenue streams, highlighting the sensitivity of the company's financial performance to external factors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, March 25, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price target for 2024?

19 brokerages have issued 1-year price objectives for Illumina's shares. Their ILMN share price targets range from $80.00 to $258.00. On average, they expect the company's stock price to reach $166.95 in the next twelve months. This suggests a possible upside of 21.6% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the start of the year. Since then, ILMN stock has decreased by 1.4% and is now trading at $137.32.
View the best growth stocks for 2024 here
.

Are investors shorting Illumina?

Illumina saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 5,210,000 shares, an increase of 5.3% from the February 29th total of 4,950,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the short-interest ratio is presently 2.9 days.
View Illumina's Short Interest
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Thursday, February, 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. The life sciences company earned $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive trailing twelve-month return on equity of 2.20% and a negative net margin of 25.78%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.14 EPS.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.45%), Vanguard Group Inc. (11.44%), Edgewood Management LLC (4.33%), Baillie Gifford & Co. (3.32%), Wellington Management Group LLP (2.04%) and GUARDCAP ASSET MANAGEMENT Ltd (1.29%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners